GATA-4 induces changes in electrophysiological properties of rat mesenchymal stem cells

Li, Hongxia; Zhou, Yafeng; Jiang, Bin; Zhao, Xin; Jiang, Tingbo; Li, Xun; Yang, Xiangjun; Jiang, Wenping

doi:10.1016/j.bbagen.2014.02.020

Cited by 5 publications

(4 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to studies of reduced MSC apoptosis following combined genetic engineering, introduction of genes that stimulate MSC differentiation has also been carried out. For instance, Zhou et al transfected MSCs with HCN2 [ 36 ] and GATA-4 [ 37 ] prior to stimulating their differentiation into pacemaker-like cells. Other studies have tested multiple gene transfections to obtain a better outcome.…”

Section: Msctt Combined With Genetic Engineering Technologymentioning

confidence: 99%

Application and Progress of Combined Mesenchymal Stem Cell Transplantation in the Treatment of Ischemic Cardiomyopathy

Hua

Liu

Tao

et al. 2015

BioMed Research International

View full text Add to dashboard Cite

Treatment of ischemic cardiomyopathy caused by myocardial infarction (MI) using mesenchymal stem cell (MSC) transplantation is a widely researched field, with promising clinical application. However, the low survival rate of transplanted cells has a severe impact on treatment outcome. Currently, research is focused on investigating the strategy of combining genetic engineering, tissue engineering materials, and drug/hypoxia preconditioning to improve ischemic cardiomyopathy treatment outcome using MSC transplantation treatment (MSCTT). This review discusses the application and progress of these techniques.

show abstract

Section: Msctt Combined With Genetic Engineering Technologymentioning

confidence: 99%

Application and Progress of Combined Mesenchymal Stem Cell Transplantation in the Treatment of Ischemic Cardiomyopathy

Hua

Liu

Tao

et al. 2015

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…In particular, GATA-4 is the pivotal controller of cardiac differentiation and regulates cell survival in the adult heart [171]. In the GATA-4-overexpressing BM-MSCs, an increase in other genes committed to myocardial differentiation was detected, and cell contraction was observed that might indicate that the abundant presence of GATA-4 paves the way for the BM-MSCs to transdifferentiate into and act as functional myocardial cells [172,173]. However, in the GATA-4 overexpressing BM-MSCs, the members of the miR-15 family were downregulated, which was translated into an increased resistance to the ischemic environment by the stimulation of anti-apoptotic Bcl-2 family members [174].…”

Section: Mscs In Cardiac-targeted Therapiesmentioning

confidence: 96%

Genetic Engineering of Mesenchymal Stem Cells for Regenerative Medicine

Nowakowski

Walczak

Janowski

et al. 2015

Stem Cells and Development

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs), which can be obtained from various organs and easily propagated in vitro, are one of the most extensively used types of stem cells and have been shown to be efficacious in a broad set of diseases. The unique and highly desirable properties of MSCs include high migratory capacities toward injured areas, immunomodulatory features, and the natural ability to differentiate into connective tissue phenotypes. These phenotypes include bone and cartilage, and these properties predispose MSCs to be therapeutically useful. In addition, MSCs elicit their therapeutic effects by paracrine actions, in which the metabolism of target tissues is modulated. Genetic engineering methods can greatly amplify these properties and broaden the therapeutic capabilities of MSCs, including transdifferentiation toward diverse cell lineages. However, cell engineering can also affect safety and increase the cost of therapy based on MSCs; thus, the advantages and disadvantages of these procedures should be discussed. In this review, the latest applications of genetic engineering methods for MSCs with regenerative medicine purposes are presented.

show abstract

“…Rat ventricular CMs were isolated from 1 to 3-day-old neonatal rats using a neonatal CM isolation kit (Worthington Biochemical Co) as previously described. 18 The cells were digested with trypsin and collagenase II before subsequent growth in Dulbecco's modified Eagle's medium (DMEM) containing 15% fetal bovine serum, 100 μg/mL penicillin, and streptomycin for 2 hours at 37°C and 5% CO 2 . Nonmyocytes attached to the bottom of the culture dishes while CMs remained in the supernatant, allowing for transfer of the CMs to new culture dishes.…”

Section: Wnt11mentioning

confidence: 99%

“…CM immunostaining was performed as previously described, 18 with minor modifications. CMs fixed on glass coverslips with 4% paraformaldehyde were incubated with mouse monoclonal anti-α-sarcomeric actinin primary antibody (clone EA-53, Sigma-Aldrich) for 1 hour at room temperature and then with a goat antimouse IgG (FITC-conjugated) secondary antibody for another 1 hour at room temperature before visualization under a BX 71 fluorescence microscope (Olympus, Tokyo, Japan).…”

Section: Immunocytochemistrymentioning

confidence: 99%

Wnt11 preserves mitochondrial membrane potential and protects cardiomyocytes against hypoxia through paracrine signaling

Jiang

et al. 2019

J of Cellular Biochemistry

Self Cite

View full text Add to dashboard Cite

We investigated the effect of Wnt11 on mitochondrial membrane integrity in cardiomyocytes (CMs) and the underlying mechanism of Wnt11‐mediated CM protection against hypoxic injury. A rat mesenchymal stem cell (MSC) line that overexpresses Wnt11 (MSCWnt11) and a control cell line transduced with empty vector (MSCNull) were established to determine the cardioprotective role of Wnt11 in response to hypoxia. Mitochondrial membrane integrity in MSCWnt11 cells was assessed using fluorescence assays. The role of paracrine signaling mediated by vascular endothelial growth factor (VEGF), basic fibroblast growth factor (b‐FGF), and insulin‐like growth factor 1 (IGF‐1) in protecting CMs against hypoxia were investigated using cocultures of primary CMs from neonatal rats with conditioned medium (CdM) from MSCWnt11. MSCWnt11 cells exposed to hypoxia reduced lactate dehydrogenase release from CMs and increased CM survival under hypoxia. In addition, CMs cocultured with CdM that were exposed to hypoxia showed reduced CM apoptosis and necrosis. There was significantly higher VEGF and IGF‐1 release in the MSCWnt11 group compared with the MSCNull group, and the addition of anti‐VEGF and anti‐IGF‐1 antibodies inhibited secretion. Moreover, mitochondrial membrane integrity was maintained in the MSCWnt11 cell line. In conclusion, overexpression of Wnt11 in MSCs promotes IGF‐1 and VEGF release, thereby protecting CMs against hypoxia.

show abstract

GATA-4 induces changes in electrophysiological properties of rat mesenchymal stem cells

Cited by 5 publications

References 37 publications

Application and Progress of Combined Mesenchymal Stem Cell Transplantation in the Treatment of Ischemic Cardiomyopathy

Application and Progress of Combined Mesenchymal Stem Cell Transplantation in the Treatment of Ischemic Cardiomyopathy

Genetic Engineering of Mesenchymal Stem Cells for Regenerative Medicine

Wnt11 preserves mitochondrial membrane potential and protects cardiomyocytes against hypoxia through paracrine signaling

Contact Info

Product

Resources

About